Literature DB >> 2952017

Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes.

M Wehling, D Armanini, T Strasser, P C Weber.   

Abstract

The in vitro effect of aldosterone on intracellular sodium and potassium concentration was investigated in human mononuclear leukocytes (HML). HML were separated from blood by a Percoll gradient and intracellular Na+ and K+ were determined before and after incubation for 1 h at 37 degrees C. The intracellular (ic) Na+ and K+ concentrations after separation of HML were 17 +/- 5 and 59 +/- 18 mmol/kg wet cells (mean +/- SD, n = 6), respectively. In the absence of aldosterone the ic Na+ concentration decreased to 12 +/- 4, whereas the ic Na+ concentration remained constant at 18 +/- 8 mmol/kg wet cells when aldosterone (1.4 nM) was added to the incubation medium. In parallel, the ic K+ concentration decreased without added aldosterone but remained constant with aldosterone. The effect of aldosterone on the ic Na+ and K+ concentrations of HML was blocked by the aldosterone antagonist canrenone (140 nM). Cortisol at a physiological concentration (40 nM) did not alter ic Na and K concentrations in these cells. The results suggest that aldosterone binding to specific receptors in human mononuclear leukocytes significantly contributes to the regulation of monovalent cation levels in these cells. Thus, this easily accessible model of HML allows study of the effects of mineralocorticoids in relation to their receptors in intact cells in normal and pathological states.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952017     DOI: 10.1152/ajpendo.1987.252.4.E505

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Effects of aldosterone and mineralocorticoid receptor blockade on intracellular electrolytes.

Authors:  Martin Wehling
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

Review 2.  [Receptor-effector relations in the effect of adosterone on mononuclear leukocytes: validation and application to various water and electrolyte imbalances in humans].

Authors:  M Wehling
Journal:  Klin Wochenschr       Date:  1989-01-04

3.  Effects of aldosterone on intralymphocytic sodium and potassium in patients with essential hypertension.

Authors:  M Wehling; S Kuhls; U Kuhnle; K Theisen
Journal:  Klin Wochenschr       Date:  1990-01-19

4.  Mineralocorticoid effector mechanism of liquorice derivatives in human mononuclear leukocytes.

Authors:  D Armanini; M Wehling; P C Weber
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

5.  Volumes and Na+/H+ antiporter activity of lymphocytes in patients with congestive heart failure.

Authors:  M Christ; V Klauss; W Pliml; K Theisen; M Wehling
Journal:  Clin Investig       Date:  1994-12

Review 6.  Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s.

Authors:  M Wehling
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

7.  Non-genomic regulation of intermediate conductance potassium channels by aldosterone in human colonic crypt cells.

Authors:  K A Bowley; M J Morton; M Hunter; G I Sandle
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

8.  Effect of canrenone and amiloride on the prooxidative effect induced by aldosterone in human mononuclear leukocytes in vitro.

Authors:  C Fiore; P Sartorato; E Pagnin; E Ragazzi; L A Calò; D Armanini
Journal:  J Endocrinol Invest       Date:  2009-05-21       Impact factor: 4.256

Review 9.  "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.

Authors:  B Pitt
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

10.  Hypothesis on a relationship between hyperaldosteronism, inflammation, somatic mutations, and autoimmunity.

Authors:  Decio Armanini; Alessandra Andrisani; Gabriella Donà; Luciana Bordin; Guido Ambrosini; Chiara Sabbadin
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-08-20       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.